Skip to main content

Table 4 Medications given to participants within the last 24 h before testing in sample II

From: Cognitive functioning in opioid-dependent patients treated with buprenorphine, methadone, and other psychoactive medications: stability and correlates

 

Buprenorphine or Buprenorphine/

Naloxone

(n= 18)

Methadone

(n= 18)

Group or time point comparison p-values

Opioid drug, dose

(M ± SD (range) )

   

T2

22 ± 5 mg

( 10 - 28 mg)

-

T2 vs. T3, ns

T3

21 ± 6 mg

( 6 - 30 mg)

-

 

T2

-

119. ± 33 mg

(80 - 180 mg)

T2 vs. T3, ns

T3

-

129 ± 33 mg

(75 - 180 mg)

 

Participants using BZD medication

   

T2/T3

78%/67%

89%/94%

ns/ns

BZD dose at T2 (M ± SD (range))

20 ± 16 mg

(0 - 60 mg)

21 ± 16 mg

(0 - 70 mg)

T2 vs. T3, ns

ns

BZD dose at T3 (M ± SD (range))

16 ± 14 mg

(0 - 40 mg)

20 ± 10 mg

(0 - 40 mg)

ns

T2 vs. T3, ns

Number of other medications with possible cognitive effects a

   

T2/T3 (M ± SD ; (range))

1.8 ± 1.1 (0 - 3)

2.2 ± 0.7 (1 -4)

ns

 

1.9 ± 1.4 (0 - 4)

2.0 ± 1.0 (1 - 4)

ns

   

T2 vs. T3, ns

  1. These included antidepressants, neuroleptics (used with anxiolytic indications), non-benzodiazepine hypnotics, and substance abuse withdrawal symptom or (non-opioid) pain relievers.
  2. C = controls, M = methadone, BN = buprenorphine or buprenorphine/naloxone
  3. > = superior than, *** = statistically significant at level p < 0.001. ** = statistically significant at level p < 0.01. * = statistically significant at level p < 0.05.